Latest B-cell chronic lymphocytic leukemia Stories
Funds Will Support Research into Treating Patients Who Have Received Chemotherapy For Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia NEW YORK, Dec.
SUNNYVALE, Calif., Dec.
Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time SAN FRANCISCO and RARITAN, N.J.,
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,
Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia NORTH CHICAGO, Ill., Dec.
Results Show Durable Responses in High Risk Patient Population MARTINSRIED, Germany, MUNICH and MONROVIA, Calif., Dec.
TG02 demonstrates ability to mobilize difficult-to-kill leukemic stem cells and render them vulnerable to chemotherapy. San Diego, California (PRWEB) December
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.